The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.

Trade war between US, Canada, and Mexico could cause severe economic damage, raise prices, and disrupt supply chains in key industries.

What we got today, of course, was advance GPD, which is the earliest measure and also the most likely to provoke a reaction in stocks.

Anxiety about the competitive threat from Chinese artificial intelligence lab DeepSeek triggered a sharp selloff in US equities on Monday, with the worst of the decline centered in tech.

The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.

The agreement, which spans up to four years, allows 17 participating countries access to Moderna’s vaccine in various formats.

The firm’s medical-loss ratio (MLR) rose to 92.4% due to Medicaid-related costs but was better than expected.

During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.

In 2023, Moderna initiated a Phase 1/2 study to assess the safety and immunogenicity of its investigational bird flu vaccine, mRNA-1018, in healthy adults aged 18 and older.

Wall Street saw a strong preference for small and mid-cap equities, with the Russell 2000 index leading the market as investors bet on more domestic-friendly policies following Donald Trump's inauguration on Jan. 20 as the 47th U.S. president.

UnitedHealth Group, the largest U.S. health insurer, reported mixed fourth-quarter 2024 results. Shares of the stock dropped nearly 6% on the day following the results. This put various ETFs in the space in focus.

Risk appetite surged on Wall Street at the end of the week, with investors ramping up stock purchases ahead of Monday's market closure for Martin Luther King Day, which is also when Donald Trump will be sworn in as the 47th U.S. president.

The company's full-year medical loss ratio, a key metric tracking the percentage of premiums paid out for medical expenses, rose to 85.5% from 83.2% in 2023.

Wall Street paused for a breather on Thursday, following Wednesday's big rally sparked by a softer-than-predicted December inflation report that fueled speculation on the Federal Reserve delivering interest rate cut